KR102240158B1 - 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도 - Google Patents
사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도 Download PDFInfo
- Publication number
- KR102240158B1 KR102240158B1 KR1020157034797A KR20157034797A KR102240158B1 KR 102240158 B1 KR102240158 B1 KR 102240158B1 KR 1020157034797 A KR1020157034797 A KR 1020157034797A KR 20157034797 A KR20157034797 A KR 20157034797A KR 102240158 B1 KR102240158 B1 KR 102240158B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- mmol
- alkyl
- thio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 **1C=NC(C=C*(*)C(*)=C2)=C2C(SC2(CCC2)C(O)=O)=C1 Chemical compound **1C=NC(C=C*(*)C(*)=C2)=C2C(SC2(CCC2)C(O)=O)=C1 0.000 description 6
- POVBCBQGBNUXBD-UHFFFAOYSA-N CC(Nc(cc12)ccc1nccc2SC1(CCC1)C(O)=O)=O Chemical compound CC(Nc(cc12)ccc1nccc2SC1(CCC1)C(O)=O)=O POVBCBQGBNUXBD-UHFFFAOYSA-N 0.000 description 1
- JYBRTIIFKUNEHZ-UHFFFAOYSA-N CCOC(C1(CCC1)Sc(c1c2)ccnc1ccc2Br)=O Chemical compound CCOC(C1(CCC1)Sc(c1c2)ccnc1ccc2Br)=O JYBRTIIFKUNEHZ-UHFFFAOYSA-N 0.000 description 1
- SIKNFKJEIOMZQN-UHFFFAOYSA-N CCOC(C1(CCC1)Sc(c1c2)ccnc1ccc2F)=O Chemical compound CCOC(C1(CCC1)Sc(c1c2)ccnc1ccc2F)=O SIKNFKJEIOMZQN-UHFFFAOYSA-N 0.000 description 1
- IZIYFOIDMRGFGS-UHFFFAOYSA-N CCOC(C1(CCC1)Sc(c1c2)ccnc1ccc2OC)=O Chemical compound CCOC(C1(CCC1)Sc(c1c2)ccnc1ccc2OC)=O IZIYFOIDMRGFGS-UHFFFAOYSA-N 0.000 description 1
- ILAQWBLUJKNILL-UHFFFAOYSA-N CCOC(C1(CCC1)Sc1ccnc(cc2)c1cc2O)=O Chemical compound CCOC(C1(CCC1)Sc1ccnc(cc2)c1cc2O)=O ILAQWBLUJKNILL-UHFFFAOYSA-N 0.000 description 1
- BEOVBLPXVFICSP-UHFFFAOYSA-N COc(cc12)ccc1nccc2Cl Chemical compound COc(cc12)ccc1nccc2Cl BEOVBLPXVFICSP-UHFFFAOYSA-N 0.000 description 1
- GGRHUZYQEPPMKD-UHFFFAOYSA-N COc(cc12)ccc1nccc2SC1(CCC1)C(O)=O Chemical compound COc(cc12)ccc1nccc2SC1(CCC1)C(O)=O GGRHUZYQEPPMKD-UHFFFAOYSA-N 0.000 description 1
- OHOHXXQPPSVCAJ-UHFFFAOYSA-N C[N]#Cc(cc12)ccc1nccc2SC1(CCC1)C(O)=O Chemical compound C[N]#Cc(cc12)ccc1nccc2SC1(CCC1)C(O)=O OHOHXXQPPSVCAJ-UHFFFAOYSA-N 0.000 description 1
- HYQAYNNLXGBRQD-UHFFFAOYSA-N Cc(cnc(c1c2)ccc2F)c1S Chemical compound Cc(cnc(c1c2)ccc2F)c1S HYQAYNNLXGBRQD-UHFFFAOYSA-N 0.000 description 1
- JKUYCINLQCCRRW-UHFFFAOYSA-N N#CCCc(cc12)ccc1nccc2SC1(CCC1)C(O)=O Chemical compound N#CCCc(cc12)ccc1nccc2SC1(CCC1)C(O)=O JKUYCINLQCCRRW-UHFFFAOYSA-N 0.000 description 1
- SWOIHRFEOQQIIB-UHFFFAOYSA-N N#Cc(cc12)ccc1nccc2SC1(CCC1)C(O)=O Chemical compound N#Cc(cc12)ccc1nccc2SC1(CCC1)C(O)=O SWOIHRFEOQQIIB-UHFFFAOYSA-N 0.000 description 1
- HDRYWSYKVOQBRC-UHFFFAOYSA-N OC(C1(CCC1)Sc(c1c2)ccnc1ccc2F)=O Chemical compound OC(C1(CCC1)Sc(c1c2)ccnc1ccc2F)=O HDRYWSYKVOQBRC-UHFFFAOYSA-N 0.000 description 1
- DMXSSNSUWXAGNE-UHFFFAOYSA-N OC(C1(CCC1)Sc(c1c2)ccnc1ccc2NC(C1CC1)=O)=O Chemical compound OC(C1(CCC1)Sc(c1c2)ccnc1ccc2NC(C1CC1)=O)=O DMXSSNSUWXAGNE-UHFFFAOYSA-N 0.000 description 1
- GRBRYCKMGXMVRY-UHFFFAOYSA-N OC(C1(CCC1)Sc1ccnc(cc2)c1cc2-c(cccc1)c1F)=O Chemical compound OC(C1(CCC1)Sc1ccnc(cc2)c1cc2-c(cccc1)c1F)=O GRBRYCKMGXMVRY-UHFFFAOYSA-N 0.000 description 1
- BNIFIUXPVRBJPR-UHFFFAOYSA-N OC(C1(CCC1)Sc1ccnc2ccncc12)=O Chemical compound OC(C1(CCC1)Sc1ccnc2ccncc12)=O BNIFIUXPVRBJPR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
- C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310174990 | 2013-05-13 | ||
| CN201310174990.6 | 2013-05-13 | ||
| PCT/CN2014/076447 WO2014183555A1 (zh) | 2013-05-13 | 2014-04-29 | 环烷基甲酸类衍生物、其制备方法及其在医药上的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160006207A KR20160006207A (ko) | 2016-01-18 |
| KR102240158B1 true KR102240158B1 (ko) | 2021-04-15 |
Family
ID=51897690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157034797A Active KR102240158B1 (ko) | 2013-05-13 | 2014-04-29 | 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9637484B2 (https=) |
| EP (1) | EP2998296B1 (https=) |
| JP (1) | JP6440690B2 (https=) |
| KR (1) | KR102240158B1 (https=) |
| CN (1) | CN104470898B (https=) |
| AU (1) | AU2014267974B2 (https=) |
| BR (1) | BR112015027303B1 (https=) |
| CA (1) | CA2923269C (https=) |
| CY (1) | CY1120515T1 (https=) |
| DK (1) | DK2998296T3 (https=) |
| ES (1) | ES2668721T3 (https=) |
| HU (1) | HUE037512T2 (https=) |
| LT (1) | LT2998296T (https=) |
| MX (1) | MX362747B (https=) |
| NO (1) | NO2998296T3 (https=) |
| PL (1) | PL2998296T3 (https=) |
| PT (1) | PT2998296T (https=) |
| TR (1) | TR201807104T4 (https=) |
| TW (1) | TWI654172B (https=) |
| WO (1) | WO2014183555A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3305768T (lt) * | 2015-05-27 | 2020-08-25 | Jiangsu Hengrui Medicine Co., Ltd. | Šlapimo rūgšties natrio druskos transporterio inhibitorius ir jo kristalinė forma |
| JP6740354B2 (ja) | 2015-10-05 | 2020-08-12 | ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク | オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法 |
| WO2017097182A1 (zh) * | 2015-12-07 | 2017-06-15 | 成都海创药业有限公司 | 喹啉类化合物及其制备方法和作为尿酸盐转运体抑制剂类药物的用途 |
| CN107286156A (zh) * | 2016-04-05 | 2017-10-24 | 江苏新元素医药科技有限公司 | 新型urat1抑制剂及其在医药上的应用 |
| WO2018090921A1 (zh) | 2016-11-16 | 2018-05-24 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
| CN108201529B (zh) * | 2016-12-16 | 2021-10-08 | 江苏恒瑞医药股份有限公司 | 一种含有尿酸转运蛋白抑制剂的药物组合物及其制备方法 |
| EP3712148B1 (en) * | 2017-11-23 | 2021-07-07 | Medshine Discovery Inc. | Crystal forms of a urat1 inhibitor, and preparation methods therefor |
| CN110452168B (zh) * | 2018-05-07 | 2022-03-15 | 中国医学科学院药物研究所 | N-苯基-n-喹啉羧酸类化合物及其制法和药物用途 |
| CN110467571B (zh) * | 2018-05-11 | 2021-02-26 | 江苏恒瑞医药股份有限公司 | 一种制备环烷基甲酸类衍生物或其可药用盐的方法 |
| CN112512526B (zh) * | 2018-11-02 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途 |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| CN114315715B (zh) * | 2020-09-29 | 2024-02-20 | 杭州中美华东制药有限公司 | 一类urat1抑制剂及其制备方法与应用 |
| AU2023285760B2 (en) * | 2021-05-19 | 2025-07-10 | Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd. | Quinoline Mercaptoacetate Sulfonamide Derivative, Intermediate, Pharmaceutical Derivative Or Formulation, And Preparation Method And Use Therefor |
| CN118439998A (zh) * | 2021-05-19 | 2024-08-06 | 江苏正大清江制药有限公司 | 一种喹啉巯乙酸磺酰胺类衍生物的制备及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| AR051780A1 (es) * | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos |
| TW200716132A (en) | 2005-05-03 | 2007-05-01 | Smithkline Beecham Corp | Novel chemical compounds |
| US7776857B2 (en) | 2007-04-05 | 2010-08-17 | Amgen Inc. | Aurora kinase modulators and method of use |
| WO2008153129A1 (ja) | 2007-06-14 | 2008-12-18 | Teijin Pharma Limited | 尿酸値低下剤 |
| ME01294B (me) | 2007-11-27 | 2013-06-20 | Ardea Biosciences Inc | Nova jedinjenja i kompozicije i metode upotrebe |
| WO2010044403A1 (ja) | 2008-10-15 | 2010-04-22 | キッセイ薬品工業株式会社 | ５員環ヘテロアリール誘導体及びその医薬用途 |
| CN102573462B (zh) | 2009-10-13 | 2014-04-16 | 维尔斯达医疗公司 | 用于降低尿酸的3位取代的化合物 |
| AR081930A1 (es) * | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| BR112012032193A2 (pt) * | 2010-06-16 | 2019-09-24 | Ardea Biosciences Inc | composto, composiçoes e métodos de uso de feniltioacetato |
-
2014
- 2014-04-29 LT LTEP14798044.5T patent/LT2998296T/lt unknown
- 2014-04-29 JP JP2016513214A patent/JP6440690B2/ja active Active
- 2014-04-29 EP EP14798044.5A patent/EP2998296B1/en active Active
- 2014-04-29 TR TR2018/07104T patent/TR201807104T4/tr unknown
- 2014-04-29 US US14/889,563 patent/US9637484B2/en active Active
- 2014-04-29 WO PCT/CN2014/076447 patent/WO2014183555A1/zh not_active Ceased
- 2014-04-29 PL PL14798044T patent/PL2998296T3/pl unknown
- 2014-04-29 KR KR1020157034797A patent/KR102240158B1/ko active Active
- 2014-04-29 CA CA2923269A patent/CA2923269C/en active Active
- 2014-04-29 NO NO14798044A patent/NO2998296T3/no unknown
- 2014-04-29 PT PT147980445T patent/PT2998296T/pt unknown
- 2014-04-29 ES ES14798044.5T patent/ES2668721T3/es active Active
- 2014-04-29 BR BR112015027303-3A patent/BR112015027303B1/pt active IP Right Grant
- 2014-04-29 DK DK14798044.5T patent/DK2998296T3/en active
- 2014-04-29 MX MX2015015393A patent/MX362747B/es active IP Right Grant
- 2014-04-29 CN CN201480001853.5A patent/CN104470898B/zh active Active
- 2014-04-29 HU HUE14798044A patent/HUE037512T2/hu unknown
- 2014-04-29 AU AU2014267974A patent/AU2014267974B2/en active Active
- 2014-05-09 TW TW103116499A patent/TWI654172B/zh active
-
2018
- 2018-06-13 CY CY20181100621T patent/CY1120515T1/el unknown
Non-Patent Citations (4)
| Title |
|---|
| Chemical Abstract Compound, STN express, RN 1065092-18-3 (Entered STN: 2008.10.23.)* |
| Chemical Abstract Compound, STN express, RN 1065092-21-8 (Entered STN: 2008.10.23.)* |
| Chemical Abstract Compound, STN express, RN 408340-41-0 (Entered STN: 2002.04.26.)* |
| JOHN, H., Journal füer Praktische Chemie, 1930, 제128권, 페이지 218-222* |
Also Published As
| Publication number | Publication date |
|---|---|
| US9637484B2 (en) | 2017-05-02 |
| CY1120515T1 (el) | 2019-07-10 |
| MX362747B (es) | 2019-02-05 |
| JP6440690B2 (ja) | 2018-12-19 |
| CA2923269C (en) | 2023-02-14 |
| ES2668721T3 (es) | 2018-05-21 |
| AU2014267974B2 (en) | 2018-08-30 |
| LT2998296T (lt) | 2018-08-10 |
| US20160108035A1 (en) | 2016-04-21 |
| HK1205118A1 (zh) | 2015-12-11 |
| CN104470898A (zh) | 2015-03-25 |
| DK2998296T3 (en) | 2018-05-22 |
| MX2015015393A (es) | 2016-03-15 |
| PL2998296T3 (pl) | 2018-12-31 |
| HUE037512T2 (hu) | 2018-08-28 |
| BR112015027303A2 (https=) | 2017-09-05 |
| PT2998296T (pt) | 2018-06-15 |
| BR112015027303B1 (pt) | 2023-04-25 |
| EP2998296B1 (en) | 2018-03-14 |
| EP2998296A1 (en) | 2016-03-23 |
| CA2923269A1 (en) | 2014-11-20 |
| KR20160006207A (ko) | 2016-01-18 |
| AU2014267974A1 (en) | 2015-11-12 |
| CN104470898B (zh) | 2016-04-06 |
| JP2016520072A (ja) | 2016-07-11 |
| TWI654172B (zh) | 2019-03-21 |
| WO2014183555A1 (zh) | 2014-11-20 |
| NO2998296T3 (https=) | 2018-08-11 |
| EP2998296A4 (en) | 2016-12-14 |
| TR201807104T4 (tr) | 2018-06-21 |
| TW201443010A (zh) | 2014-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102240158B1 (ko) | 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도 | |
| AU2019237992A1 (en) | Oxadiazole transient receptor potential channel inhibitors | |
| JPH04235974A (ja) | 新規なイミダゾール誘導体、それらの製造法、得られる新規な中間体、それらの薬剤としての使用及びそれらを含有する製薬組成物 | |
| EP3172212B1 (en) | Aldosterone synthase inhibitors | |
| JP2011526295A (ja) | ５員および６員複素環化合物 | |
| EP3585772B1 (en) | 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors | |
| JP6782763B2 (ja) | 新規のピリジニウム化合物 | |
| WO2022152853A1 (en) | Antagonists of mrgx2 | |
| KR20120101551A (ko) | Ｍｇｌｕｒ５ 수용체의 알로스테릭 조절자로서 바이사이클릭 티아졸 | |
| JP2025540714A (ja) | Ｌｐａ受容体活性と関連する状態を処置するための化合物および組成物 | |
| JP6914974B2 (ja) | 腎疾患、心血管疾患、および線維性障害の治療に有用な二環式イミダゾール誘導体 | |
| AU2023225907A1 (en) | Compounds and compositions for treating conditions associated with lpa receptor activity | |
| TWI912295B (zh) | Ｐｈｄ抑制劑化合物、組成物及使用方法 | |
| JP2007507464A (ja) | 新規のアミノピリジン誘導体 | |
| TW202608874A (zh) | 一種五元雜環類化合物、藥物組合物及其應用 | |
| JP2025530470A (ja) | リン酸化アリール構造を有する小分子化合物とその使用 | |
| HK1205118B (en) | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof | |
| HK40061190B (zh) | 苯并噻吩类化合物及其制备方法和用途 | |
| HK1232870B (en) | Aldosterone synthase inhibitors | |
| HK1232870A1 (en) | Aldosterone synthase inhibitors | |
| HK1165415A (en) | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R13-asn-PN2301 St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 6 |